Menu Search
Equities

SanBio Co Ltd

4592:TYO

SanBio Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,080.00
  • Today's Change47.00 / 4.55%
  • Shares traded841.20k
  • 1 Year change+135.81%
  • Beta1.2518
Data delayed at least 20 minutes, as of Nov 08 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform1
Hold2
Sell0
Strong Sell2

Share price forecast in JPY

The 5 analysts offering 12 month price targets for SanBio Co Ltd have a median target of 1,100.00, with a high estimate of 2,500.00 and a low estimate of 270.00. The median estimate represents a 1.85% increase from the last price of 1,080.00.
High131.5%2,500.00
Med1.9%1,100.00
Low-75.0%270.00

Earnings history & estimates in JPY

On Sep 17, 2024, SanBio Co Ltd reported 2nd quarter 2025 losses of -16.96 per share. This result exceeded the -18.40 consensus loss of the one analyst covering the company and exceeded last year's 2nd quarter results by 5.19%.
The next earnings announcement is expected on Dec 16, 2024.
Average growth rate-302.88%
SanBio Co Ltd reported annual 2024 losses of -40.48 per share on Mar 18, 2024.
Average growth rate+12.15%
More ▼

Revenue history & estimates in JPY

SanBio Company Limited did not report revenues for the full year 2024. However, during the prior year the company reported revenues of 0.00.
Average growth rate-25.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.